Pyrrolidine

Pyrrolidine

SCHEMBL2531422

C1CCNC1.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Pyrrolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
LMNA P02545 4/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PKM P14618 3/20 0.46
POLB P06746 1/20 0.46
CYP2D6 P10635 3/20 0.45
GAA P10253 1/20 0.45
SNCA P37840 1/20 0.44
KMT2A Q03164 2/20 0.43
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
MMP2 P08253 2/20 0.42
MMP1 P03956 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrrolidine SCHEMBL16241174 0.98 ALDH1A1 (0.45) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Piperidine SCHEMBL4867261 0.98 ALDH1A1 (0.45) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Piperidine SCHEMBL631560 0.98 ALDH1A1 (0.45) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Piperidine SCHEMBL16927692 0.96 ALDH1A1 (0.44) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Azetidine SCHEMBL28290955 0.96 ALDH1A1 (0.49) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Aziridine SCHEMBL5185484 0.94 ALDH1A1 (0.50) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Piperazine SCHEMBL5875357 0.92 ALDH1A1 (0.49) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Piperazine SCHEMBL7635861 0.92 ALDH1A1 (0.49) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Cyclohexane SCHEMBL27563472 0.86 GAA (0.54) ALDH1A1LMNAHTTSMN1; SMN2KDM4E
Cyclopropane SCHEMBL2101355 0.86 GAA (0.54) ALDH1A1LMNAHTTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119080615-A Method for preparing long-chain dibasic acid or dibasic ester 中国科学院大连化学物理研究所 2024-12-06 CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
CN-119080615-A Method for preparing long-chain dibasic acid or dibasic ester 中国科学院大连化学物理研究所 2024-12-06 CN disclosed
CN-108290881-A Therapeutic compounds and methods of use thereof 健泰科生物技术公司 2018-07-17 CN disclosed
CN-108069955-A 3- pyridyl group -4- benzothiazolyls pyrazole derivatives, its preparation method and its application in medicine 江苏恒瑞医药股份有限公司 2018-05-25 CN disclosed
US-8877927-B2 Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl proteinase inhibitors GRUNENTHAL GMBH (DE) 2014-11-04 US disclosed
CN-102112473-B Pyrrolidinyl-alkyl-amide derivatives, process for their preparation and their therapeutic use as CCR3 receptor ligands SANOFI AVENTIS 2014-08-20 CN disclosed
US-8629287-B2 Process for the sulfinylation of a pyrazole derivative BASF SE (DE) 2014-01-14 US disclosed
EP-2081909-B1 PROCESS FOR THE SULFINYLATION OF A PYRAZOLE DERIVATIVE BASF SE (DE) 2013-01-09 EP disclosed
EP-2081919-B1 TETRAHYDROFURO [3, 2-B]PYRR0L-3-0NE INTERMEDIATES AMURA THERAPEUTICS LTD (GB) 2012-05-23 EP disclosed
EP-2081919-A1 TETRAHYDROFURO [3, 2-B]PYRR0L-3-0NE INTERMEDIATES Amura Therapeutics Limited (GB) 2009-07-29 EP disclosed
EP-2081909-A1 PROCESS FOR THE SULFINYLATION OF A PYRAZOLE DERIVATIVE BASF SE (DE) 2009-07-29 EP disclosed
EP-2046797-A1 FURO [3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS Amura Therapeutics Limited (GB) 2009-04-15 EP disclosed
US-7402684-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENECTICS EHF. (IS) 2008-07-22 US disclosed
EP-1926708-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION Decode Chemistry, Inc. (US) 2008-06-04 EP disclosed
WO-2008055879-A1 PROCESS FOR THE SULFINYLATION OF A PYRAZOLE DERIVATIVE BASF SE (DE) 2008-05-15 WO disclosed
WO-2008007127-A1 FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 WO disclosed
WO-2008007132-A1 TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES AMURA THERAPEUTICS LIMITED (GB) 2008-01-17 WO disclosed
WO-2007040681-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2007-04-12 WO disclosed
WO-2007040682-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF. (IS) 2007-04-12 WO disclosed